



() -

*

() : _____

() : _____
E2 FSH LH

() (/ ±) : _____
()

/ () (±) / ()
() ()

() : _____

/ / : / / :

*

/

(TBI)

(Little BU-CY) .()

.()

Little BU-CY

.()
)
(TBI) (

Graft Versus Host Disease

BU-CY	CML
BU-CY	AML
BU-CY	A LL
CY	AA
CY+VP 16+AL	MM
Car+ CY+ VP 16	
BU-CY	MDS
CEAM	
) MM () AA () ALL () CML () AML :	
A () E () C () Car () AL () CY () BU () MDS ()	
	.() M ()

1

1

FSH LH ()

\pm) . (/ \pm :

(Paired T-Test)

P_≤ /

P value	P value				
/ *	/ *	±	±	±	LH (mIU/ml)
/ *	/ *	±	±	±	FSH (mIU/ml)
/ *	/	±	±	±	(ng/ml)
/	/	±	±	±	(ng/ml)

/ FSH

(GVHD)

() GVHD ()

/

GVHD . () ()

GVHD ()

P value	P value				
/ *	/ *	±	±	±	LH (mIU/ml)
/ *	/ *	±	±	±	FSH (mIU/ml)
/	/	±	±	±	(ng/ml)
/	/	/ ± /	/ ± /	±	(ng/ml)
/	* /	±	±	±	(pg/ml)

P < / *

()

)

(

BU/CY (Premature Ovarian Failure)

()

()

()

()

POF

()

BU/CY

/

/

.()

.()

(Bone Marrow Transplantation)

()

()
FSH LH)

()
()

()

()

.() (%)

.()

BMT
BMT .()
)

(/) (.()

GVHD .()
() TBI

BU/CY .()

.()
()

/

FSH () ()

TBI () () GVHD

FSH LH ()

Inhibin B

() GnRH-a

() ()

:

()

FSH

References:

1. Shalet SM, Didi M, Oglivy – Stuart AL, et al. Growth and endocrine function after bone Marrow transplantation. Clinical Endocrinology 1995; 42: 333 – 9.

2. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasm in long – term survivors of bone marrow Transplantation. Ann Intern Med 1999; 131: 738 – 44.

3. Chatterjee R, Goldstone AH. Gonadal damage and effects on fertility in adult patients with Hematological malignancy undergoing stem cell transplantatoion. *Bone Marrow Transplant* 1996; 17: 5-11.
4. Schubert MA, Sullivan KM, Schubert MM, et al. Gynecological abnormalities following Allogenic bone marrow transplantation. *Bone Marrow Transplant* 1990; 5: 425-30.
5. Couto-Silva AC, Trivin C, Thibaud E, et al. Factors affecting gonadal function after bone Marrow transplantation during childhood. *Bone Marrow Transplant* 2001; 28: 67-75.
6. Sanders JE, Buckner CD, Amos D, et al. Pregnancies following high dose cyclophosphamide With or without high – dose busulfan or total – body irradiation and bone marrow transplantation. *Blood* 1996; 87: 3045-52.
7. Afify A, Shaw PJ, Calvano – Harding A, et al. Growth and endocrine function in children With acute myeloid leukemia after bone marrow transplantation using busulfan / Cyclophosphamide. *Bone Marrow Transplant* 2000; 25: 1087-92.
8. Sklar CH, Boulad F, Small T, et al. Endocrine complications of pediatric stem cell Transplantation. *Front Biosci* 2001; 6: 17 – 22.
9. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft – versus – hast – disease and other late Complications of bone marrow transplantation. *Semin Hematol* 1991; 28: 250-9.
10. Wingard JR, Plotnick LP, Freemer CH, et al. Growth in children after bone marrow Transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body Irradiation. *Blood* 1992; 79 Suppl 4: 1068-73.
11. Chatterjee R, Mills W, Katz M. Prospective study of pituitary – gonadal function to evaluate Short – term effects of ablative chemotherapy or total body irradiation with autologous or Allogenic marrow transplantation in postmenarcheal female patients. *Bone Marrow Transplant* 1994; 13: 511-7.
12. Blumenfeld Z, Avivi I, Ritter M, et al. Preservation of fertility and ovarian function and Minimizing chemotherapy-induced gonadotoxicity in young women. *J Soc Gynecol Invest* 1999; 6: 229-39.
13. Chapman RM, Sutcliffe SB, Maipas JS. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I: Hormonal function. *J AM Med Assoc* 1979; 242: 1877-81.
14. Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. *Semin Oncol* 1982; 9: 84-93.
15. Devita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with Chemotherapy. *Ann Intern Med* 1998; 92: 587-95.
16. Kreuser ED, Xirus N, Hetzel WD, et al. Reproductive and endocrine gonadal capacity in Patients treated with copp chemo therapy of Hodgkin's disease. *J Cancer Ros Clin Oncol* 1987; 113: 260-6.
17. Oktay K, Kan MT, Rosenwaks Z. Recent progress in oocyte and ovarian tissue Cryopreservation and transplantation. *Curr Opin Obstet Gyncol* 2001; 13: 263 – 8.
18. Rivkees SA, Crawford JD. The relationship of gonadal damage. *J Am Med Assoc* 1988; 259: 2123-5.
19. Ataya K, Rao LV, Laurence E, et al. Luteinizing hormone – releasing hormone agonist Inhibits cyclophosphamide. *Biol Reprod* 1995; 52: 365-72.
20. Averette HE, Boyce GM, Girl MA. Effects of cancer chemotherapy on gonadal function and Reproductive capacity. 1990; 40: 199-209.
21. Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for Cancer. *Semin Oncol* 1989; 16: 425-36.
22. Morgenfeld MC, Goldberg V, Parisier H, et al. Ovarian Lesions due to cytostatic agents during The treatment of Hodgkin's disease. *Surg Gynecol Obstet* 1972; 134: 826-8.
23. Schilsky RL, Lewis BJ, Sherins RJ, et al. Gonadal dysfunction in patients receiving Chemotherapy for cancer. *Ann Intern Med* 1980; 93: 109-14.
24. Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure. *New Engl J Med* 1973; 289: 1159-62.
25. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. *Ann Med* 1997; 29: 199-206.
26. Wingard JR, Miller DF, Santos GW. Testicular function after busulfan (BU) plus Cyclophosphamide. *J Cell Biochem* 1992; 16 A: 215, Abstr D 618.
27. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for Aplastic anemia or leukemia. *Clin Oncol* 1988; 6: 813-7.
28. Hinterberger-Fischer M, Kier P, Kalhs P, et al. fertility, pregnancies and offspring Complications after bone marrow transplantation. *Bone Marrow Transplant* 1991; 7: 5-9.
29. Jacob A, Goodman A, Holmes J. Fertility after bone marrow transplantation following Conditioning with cyclophosphamide and total body irradiation. *Bone Marrow Transplant* 1995; 15: 483-5.
30. UIdall PR, Kerr DNS, Tacchi D. Sterility and cyclophosphamide. *Lancet* 1972; 1: 693-4.

-
31. Sanders JE, Buckner CD, Leonard JM, et al. Late effects on gonadal function of Cyclophosphamide, total body irradiation, and marrow transplantation. *Transplantation* 1983; 36: 252-5.
32. Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow Transplantation. *J Clin Oncol* 1998; 16: 2359-63.
33. Spinelli S, Chiodi S, Bacigalupo A, et al. ovarian recovery after total – body irradiation and Allogeneic bone marrow transplantation: Long – term follow – up of 79 females. *Bone Marrow Transplant* 1994; 14: 373-80.
34. Cohen A, Van Lint MT, Lavagetto A. Pubertal development and fertility in children after Bone marrow transplantation. *Bone Marrow Transplant* 1991; suppl 8: 16-20.
35. Wallace WH, Shalet SM, Hendry JH. Ovarian Failure following abdominal irradiation in Childhood radiosensitivity of the human oocyte. *Br J Radiol* 1989; 62: 995-8.
36. Baker T. Radiosensitivity of mammalian oocytes with particular reference to the human Female. *Am J Obstet Gynecol* 1971; 110: 746-61.
37. Damewood MD, Grochow LB. Fertility after chemotherapy / radiation. *Fertil Steril* 1989; 45: 443-9.
38. Tauchmonova L, Selleri C, De Rosa G, et al. High prevalence of endocrine dysfunction in long – Term survivors after allogeneic bone marrow transplantation for hematological diseases. *Cancer* 2002; 95: 1076-84.
39. Grigg AP, MC Lach Lan R, Zaga J, et al. Reproductive status in long – term bone marrow Transplant survivors receiving busulfan – cyclophosphamide (120 mg/kg). *Bone Marrow Transplant* 2000; 26: 1089-95.
40. Heimpel H, Arnold R, Hetzel D, et al. Gonadal function after bone marrow transplantation in Adult male and female patients. *Bone Marrow Transplant* 1991; 8 suppl 1: 21-4.
41. Mertens AC, Ramsay NKC, Kouris S, et al. Patterns of gonadal dysfunction following bone Marrow transplantation. *Bone Marrow Transplant* 1998; 22: 345-50.
42. Wingard JR, Curbow B, Baker F, et al. Sexual satisfaction in survivors of bone marrow Transplantation. *Bone Marrow Transplant* 1992; 9: 185-90.
43. Syrjala KL, Roth-Roemer SL, Abrams JR. Prevalence and predictors of sexual dysfunction in long – term survivors of marrow transplantation. *J Clin Oncol* 1998; 16: 3148-57.
44. Clark ST, Radford JA, Crowther D, et al. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug regimen. *J Clin Oncol* 1995; 13: 134-9.
45. Sanders JE and the Seattle Marrow Transplant Team. The impact of marrow transplant Preparative regimens on subsequent growth and development. *Semin Haematol* 1991; 28: 24-9.
46. Brice P, Pautier P, Marolleau JP. Pregnancy after autologous stem cell transplantation for Malignant lymphomas. Proceedings of the 20th Meeting of the EBMT. *Bone Marrow Transplant* 1994; 460A.
47. Ataya KM, Mckanna JA, Weintraub AM, et al. Prevention of chemotherapy – induced ovarian Follicular loss in rats. *Cancer Res* 1985; 45: 3651-6.
48. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of Chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin – A and B – as markers. *Mol Cell Endocrinol* 2002, 187: 93-105.